Xie Boxiong, Yang Yang, He Wenxin, Xie Dong, Jiang Gening
Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University, Shanghai, China.
Interact Cardiovasc Thorac Surg. 2013 Sep;17(3):455-9. doi: 10.1093/icvts/ivt251. Epub 2013 Jun 7.
Multidrug-resistant tuberculosis (MDR-TB), defined as tuberculosis resistant to at least isoniazid and rifampicin in vitro, poses a significant challenge to the control of TB worldwide. Despite global efforts to control tuberculosis, it remains the leading cause of death from an infectious agent. Although modern tuberculosis treatment relies on chemotherapy, surgery is accepted as adjuvant treatment for multidrug-resistant tuberculosis.
In a retrospective cohort study, 43 MDR-TB patients (28 males and 15 females: mean age 45.3 years) who underwent pulmonary resection between January 1993 and December 2011 were reviewed. Every patient with well-localized, cavitary lesions showed sputum-positive preoperatively. Individually tailored treatment regimens were selected at a once-weekly staff conference following review of the patient's case history and drug susceptibility results. The variables that affected treatment outcomes were identified through multivariate regression analysis.
There was no surgical mortality. Forty (93.0%) patients demonstrated sputum conversion and/or remained negative after surgery. Each patient had completed treatment, and during a mean of 81 follow-up months (range 18-214 months), 1 patient relapsed. This patient was cured after another course of treatment. Operative procedures included 30 (69.8%) lobectomies, 2 (4.7%) bilobectomies, 8 (18.6%) pneumonectomies and 3 (6.98%) lobectomies plus segmentectomy. There were no operation-related deaths, and there were five major postoperative complications (11.6%). Overall, 40 of 43 (93.0%) MDR-TB patients remained free of TB following surgery. The duration of chemotherapy before surgery had correlation with postoperative outcome (P = 0.001).
The proper selection of the patients and early decision for surgical intervention can achieve a high success rate of pulmonary MDR-TB with well-localized pulmonary cavities.
耐多药结核病(MDR-TB),即体外对至少异烟肼和利福平耐药的结核病,对全球结核病控制构成重大挑战。尽管全球努力控制结核病,但它仍是感染性疾病致死的主要原因。虽然现代结核病治疗依赖化疗,但手术被视为耐多药结核病的辅助治疗方法。
在一项回顾性队列研究中,对1993年1月至2011年12月期间接受肺切除术的43例耐多药结核病患者(28例男性和15例女性:平均年龄45.3岁)进行了回顾。每例局限性空洞性病变患者术前痰菌均为阳性。在每周一次的工作人员会议上,根据患者病史和药敏结果回顾,选择个体化定制的治疗方案。通过多因素回归分析确定影响治疗结果的变量。
无手术死亡病例。40例(93.0%)患者术后痰菌转阴和/或持续阴性。所有患者均完成治疗,在平均81个月的随访期(范围18 - 214个月)内,1例患者复发。该患者经另一疗程治疗后治愈。手术方式包括30例(69.8%)肺叶切除术、2例(4.7%)双肺叶切除术、8例(18.6%)全肺切除术和3例(6.98%)肺叶切除术加肺段切除术。无手术相关死亡病例,术后有5例严重并发症(11.6%)。总体而言,43例耐多药结核病患者中有40例(93.0%)术后无结核病复发。术前化疗时间与术后结果相关(P = 0.001)。
正确选择患者并尽早决定手术干预,可使局限性肺空洞的耐多药肺结核手术成功率较高。